Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onvansertib + Abiraterone in mCRPC
NCT03414034Phase 2Completed
- Sponsor
- Cardiff Oncology
- Start
- Aug 2018
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of onvansertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Cardiff Oncology. Started Aug 2018; status: completed.
02
Drugs
onvansertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03414034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414034.